Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,244 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 11.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,897 shares of the biopharmaceutical company’s stock after acquiring an additional 3,244 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Catalyst Pharmaceuticals were worth $774,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $29,000. Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $64,000. GAMMA Investing LLC grew its holdings in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 579 shares during the period. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $104,000. Finally, New Vernon Capital Holdings II LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $122,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $22.22 on Wednesday. The firm’s fifty day moving average is $22.52 and its two-hundred day moving average is $22.84. The firm has a market cap of $2.71 billion, a PE ratio of 14.15, a price-to-earnings-growth ratio of 0.89 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a twelve month low of $15.59 and a twelve month high of $26.58.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider directly owned 41,081 shares in the company, valued at approximately $1,085,360.02. The trade was a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gary Ingenito sold 44,000 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the sale, the insider owned 68,873 shares of the company’s stock, valued at $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 247,924 shares of company stock worth $5,879,369 in the last ninety days. 10.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.